Company Overview
Autolus Therapeutics plc operates as a clinical-stage biopharmaceutical entity focused on developing T cell therapies designed to treat cancer and autoimmune diseases within the United Kingdom and international markets. The company functions within the Healthcare sector and specifically the Biotechnology industry, positioning itself to address high-value therapeutic areas through advanced cellular immunology programs. As of the latest available data, the organization maintains a market capitalization of $353.97M, generates $51.13M in annual revenue, and employs 647 individuals. These valuation and operational metrics indicate that Autolus holds a mid-sized capitalization typical of clinical-stage biotechnology firms that are investing heavily in research and development while yet to achieve significant commercial scale, reflecting a business model where current revenues primarily support pipeline advancement rather than mass-market product sales.
Financial Health
Autolus Therapeutics reported a trailing twelve-month revenue of $51.13M, which contrasts sharply with a net income of -$224,802,000 and an EBITDA of -$264,679,008, revealing a cost structure where expenses significantly exceed total revenue generation. The company's free cash flow stands at -$267,752,128, indicating a substantial cash outflow that limits immediate financial flexibility and necessitates reliance on existing cash reserves or external financing to fund ongoing clinical trials and operational activities. Margin analysis shows a gross margin of -264.8%, an operating margin of -337.9%, and a profit margin of 0.0%, figures that collectively demonstrate the extreme expense intensity inherent in the early-stage development of complex T cell therapies like obecabtagene autoleucel (AUTO1). On the balance sheet, the company holds $367.41M in cash against $325.18M in debt, resulting in a debt-to-equity ratio of 122.50, which suggests a highly leveraged position given the negative earnings, although the cash balance provides a critical buffer against current obligations. Liquidity is supported by a current ratio of 6.19, indicating that the company possesses more than six times the current assets needed to cover its short-term liabilities, suggesting strong short-term solvency despite the leverage. Return on equity is recorded at -60.6% and return on assets at -23.0%, metrics that reveal management is currently generating negative returns on both shareholder equity and the asset base as the company prioritizes capital deployment into clinical programs over profitability.
Valuation Assessment
Valuation metrics for Autolus present a complex picture, with a trailing P/E ratio listed as N/A due to the lack of positive net income, while the forward P/E is reported at -1.59, implying that the market prices the stock based on anticipated future earnings that are not yet realized. The price-to-book ratio is 1.33, indicating that the market values the company at 33% above its book value, which often occurs in biotechnology stocks where the market places a premium on intellectual property and pipeline potential rather than current book assets. Alternative valuation multiples show a price-to-sales ratio of 6.92 and an EV/EBITDA of -1.18, suggesting that investors are valuing the company primarily on its revenue generation capacity and potential future cash flows rather than current profitability or earnings power. The stock has traded between a 52-week low of $1.10 and a 52-week high of $2.70, meaning the current price sits at the upper end of this historical range but remains below the peak valuation seen over the past year. The beta value is 2.00, which signifies that the stock exhibits high price volatility, theoretically moving twice as much as the broader market in response to general market fluctuations or sector-specific news.
Growth & Income
Autolus Therapeutics reports N/A for revenue growth year-over-year and N/A for earnings growth year-over-year, reflecting the typical profile of a clinical-stage company where growth rates are not yet applicable due to the absence of a mature commercial product line or consistent historical data. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the organization retains all earnings and cash flow to reinvest into its clinical-stage programs rather than distributing income to shareholders. This reinvestment strategy is consistent with the operational stage of the business, where capital is directed toward advancing obecabtagene autoleucel and other T cell therapies through clinical trials rather than providing current income returns. Consequently, the overall growth and income profile is defined by the potential for future commercialization rather than current revenue expansion or dividend income, with the company's value contingent entirely on the successful progression of its therapeutic pipeline.